| Today’s Big NewsDec 3, 2024 |
|
Tuesday, December 10, 2024 | 12pm ET / 9am PT Mammalian synthetic biology has shown that key principles of biological regulation can be rewritten to control gene expression and produce complex, cellular behaviors. Recently, these core principles have now been applied at the protein level. Join us to learn about these latest approaches, and what the mean for cancer biology, immunology, and neuroscience. Sign up now!
|
|
| By Darren Incorvaia Human genetics biotech Maze Therapeutics has navigated the biotech world’s tricky fundraising landscape to land a $115 million series D round. |
|
|
|
By Fraiser Kansteiner With Republicans sweeping the White House and both chambers of Congress, the life sciences industry could be due for some changes in key areas over the coming years, one analyst group contends. |
By Gabrielle Masson After pausing work on a rare cancer asset, Relay Therapeutics is passing the baton to Elevar Therapeutics. The two have signed a deal worth up to $500 million biobucks that gives Elevar licensing rights to an investigational oral small molecule designed to treat solid tumors. |
By Conor Hale Each year, we assemble our list of marquee names in the Fierce 15—featuring the most innovative private companies and startups in the industry, and the ones we feel will have an outsized impact on their field. |
|
The right funding at the right time is crucial for life sciences companies that want to fuel innovation and scale operations. Download this free whitepaper to drive innovation, expand operations and lead your organization to further success.
|
|
By Zoey Becker The former FDA commissioner pointed to the threat of measles if vaccination rates were to decline by 5%. |
By Conor Hale In what the company described as an industry-first, the Acuson Sequoia software also includes tools for assessing liver tissue, including fat content. |
By Fraiser Kansteiner Chicago’s Cour Pharmaceuticals—recently honored as one of Fierce Biotech’s 2024 Fierce 15—is bringing its immunology mission to the fore with a new deal featuring Swiss drug juggernaut Roche. |
By Kevin Dunleavy Bristol Myers Squibb has enlisted three-year-old Massachusetts biotech AI Proteins to use its artificial intelligence-driven platform to discover and develop therapeutic miniproteins for two undisclosed targets. |
By Joseph Keenan Over-the-counter drug giant Reckitt shelled out £155 million ($200 million) to expand its manufacturing facility in North Carolina, where it produces the popular cold and flu drug Mucinex. |
By Conor Hale GE HealthCare plans to take full control of Nihon Medi-Physics, maker of diagnostic radiopharmaceuticals and molecular imaging agents. The company had previously split ownership of the Tokyo-based nuclear medicine outfit down the middle with Sumitomo Chemical. |
By Zoey Becker The latest dataset for Janux' JANX007 showed that all 16 patients with heavily pre-treated metastatic prostate cancer achieved a 50% decline in prostate-specific antigens. The result sent the biotech's shares soaring nearly 60%. |
By Fraiser Kansteiner On the heels of similar deals in the U.S. and the European Union, the United Kingdom is filling up its coffers with doses of bird flu immunizations from Australia’s CSL Seqirus. To prepare for a potential future pandemic, the U.K. has inked an accord with CSL Seqirus to acquire more than 5 million doses of the company’s H5 influenza shot. |
By Kevin Dunleavy As part of its second reorganization in 16 months, Agenus will offer CDMO services at its two manufacturing sites in California, performing production of biologics products for clients. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce editors discuss our special report celebrating 10 women driving change in clinical research, business development, venture capital, and more |
|
|---|
|
|
|
The European orphan drug market presents a significant opportunity, with forecasts predicting substantial growth in the coming years. Early access programs (EAPs) have emerged as a critical strategy for successfully launching rare disease therapies in this complex and diverse market. Access this whitepaper to learn more.
|
|
| WhitepaperWe interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
